
Genentech shares positive results from phase 3 trial for breast cancer treatment
Betsy Goodfellow | December 5, 2023 | News story | Research and Development | Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the investigational therapy, inavolisib, in combination with palbociclib and fulvestrant as a potential treatment for patients with PIK3CA-mutated, hormone receptor (HC)-positive, HER2-negative, endocrine-resistant, locally advanced or metastatic breast cancer.
The trial met its primary endpoint of progression-free survival (PFS) and demonstrated a statistically significant and clinically meaningful improvement compared to palbociclib and fulvestrant alone.
Overall survival (OS) data was immature at this point of analysis but a clear positive trend was observed, with follow-up expected to continue until the next analysis.
The drug combination was well tolerated, with adverse effects remaining consistent with the known safety profiles of all of the drugs. No new safety signals were observed.
“These pivotal study results for this inavolisib combination could represent a transformative medical advance for people with PIK3CA-mutated HR-positive breast cancer,” said Levi Garraway, MD, PhD, Genentech’s chief medical officer and head of Global Product Development. “We look forward to expanding our portfolio of breast cancer medicines into the HR-positive space and bringing this potentially best-in-class new treatment option to patients as quickly as possible.”
Betsy Goodfellow
Related Content

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …






